01:00 PM EDT, 08/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $138 from $110 on a multiple of 16.0x our 2026 EPS, above Gilead's five-year historical forward P/E average of 10.9x, justified by its strengthening outlook. We lift our 2025 EPS estimate to $8.15 from $7.98 and our 2026 EPS estimate to $8.61 from $8.50. GILD reported better-than-expected Q2 results yesterday, while raising its revenue and outlook for full-year 2025, signaling confidence in the core HIV business and growth prospects in the back half of the year, in our view. The HIV segment, GILD's primary growth driver, had a very robust Q2, in our view, with sales increasing 7% Y/Y to $5.1B, led by key drugs Biktarvy (+9% Y/Y) and Descovy's (+35% Y/Y) solid performances. We find the company's R&D strength coupled with its strong commercial execution remarkable and key differentiators vs. peers. Following the successful FDA approval and early uptake of Yeztugo, the biannual shot for to prevent HIV, we expect more solid sales contributions in 2H driven by increasing demand.